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Role of LFA-l/ICAM-1 in 
interIeukin-2-stimuIated lymphocyte proliferation
Major adhesion routes between lymphoid cells involve the receptor/ligand pairs 
LFA-l/ICAM-1 and CD2/LFA-3, in addition to VLA or CD44 molecules. In this 
study we evaluated the role of these adhesion receptors in the proliferative 
response of lymphoid cells to interleukin-2 (IL-2). Blocking studies were 
performed with a panel of monoclonal antibodies (mAb) directed against these 
adhesion molecules. Selective inhibition of recombinant (r)IL-2-induced cell 
proliferation was observed with mAb directed against the a or ¡3 subunit of LFA-1 
or to its ligand ICAM-1. Interestingly, rIL-2-induced proliferation was also 
inhibited by NKI-L16, an anti-la antibody known to enhance cell-cell interac­
tion. Resting lymphocytes were preferentially susceptible to the inhibition, 
particularly in an early phase of culture and when stimulated with a relatively low 
dose of rIL-2. By using mAb that specifically could block distinct rIL-2 activation 
pathways, LFA-l/ICAM-1 interaction was found to be required for p55 IL-2 
receptor (IL-2R)-mediated interaction of rIL-2 with its high-affinity receptor, but 
not for p75 IL-2R-rnediated responses. Furthermore, it was shown that the rIL-2 
response of T lymphocytes, but not of natural killer cells, was dependent on 
LFA-l/ICAM-1 interaction. This suggests that LFA-l/ICAM-1 interaction is 
required for an optimal iiL-2 response of cells capable of IL-2 secretion. Our data 
provide evidence for the hypothesis that adhesion receptor-directed release of 
IL-2 may result in a locally high concentration of IL-2 that triggers high-affinity 
IL-2R signaling and up-regulates p55 IL-2R to enhance cytokine responsive­
ness.
1 Introduction
Interleukin-2 (IL-2) is aT cell-derived cytokine involved in 
the proliferation and differentiation of T lymphocytes, B 
lymphocytes, NK cells as well as monocytes [1-4]. Upon 
antigen recognition by T lymphocytes, the induction of 
both IL-2 and IL-2R gene expression allows subsequent 
proliferation of activated clones, either in an autocrine or 
paracrine fashion [1, 5]. The IL-2R is composed of a 
complex of at least two different subunits, the a chain (p55 
IL-2R, CD25) [6, 7] which has low affinity (Kd 10-8 m) and 
the (3 chain (p75 IL-2R) [8] which has intermediate affinity 
(K d  10~9 m ) for IL-2. Both subunits, together with a re­
cently identified p64 y chain [9], when complexed with IL-2, 
form a high affinity IL-2R (Kd 10“11 M [1, 8, 9]). The a 
chain is thought to function as a helper molecule, required 
to concentrate IL-2 on the surface of the cell and to enhance 
the affinity of the ¡5 chain for IL-2 upon complexation 
[10-13].The ¡3 chain, which has a long intracellular domain, 
is responsible for internalization of the complex and is 
supposed to transduce the IL-2 signal into the cell [8, 14].
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Upon activation by IL-2, the up-regulation of the p55 IL-2R 
by far exceeds that of the p75 IL-2R [1, 15,16]. Peripheral 
blood NK cells and CD8+ T lymphocytes, both of which 
express p75 IL-2R [17], can be directly stimulated by IL-2 
[2, 18-20].
Cellular immune functions are not only dependent on 
antigen/receptor and cytokine/receptor interactions, but 
are also determined by appropriate cell-cell contact 
[21, 22]. The importance of the interaction between the 
adhesion receptor LFA-1 (CDlla/CD18) and its ligand 
ICAM-1 (CD54) in TCR-mediated immune responses has 
been established and this adhesion pathway was found to 
contribute to both signaling and adhesion [23-34], Anti- 
CD3-stimulated T cell proliferation was found to be regu­
lated, either by LFA-1 mAb [30] or using purified ICAM-1 
as a ligand [31], at the level of IL-2 production and p55 
IL-2R expression. However, it remains to be established 
whether LFA-l/ICAM-l-mediated cell-cell contact, apart 
from its role in TCR-dependent signal transduction 
[30-34], directly participates in the interaction of IL-2 with 
its receptor(s). ICAM-1 (CD54), usually weakly expressed 
on hemopoietic cells, is strongly induced after stimulation 
of the cells with mediators of inflammation, e.g. IL-1 or 
IFN-y [35], and also IL-2 [36-38]. As described previously, 
activation of LFA-1 by TCR triggering, is a prerequisite foi- 
interaction with ICAM-1 [39, 40] and can also be induced 
by stimulation with IL-2 as the primary stimulus [38, 41, 
42]. Activation of lymphocytes by IL-2 results in the 
expression of the L16 epitope on LFA-1 which is thought to 
be associated with a conformational change of the molecule 
[43]. Recently, we showed that IL-2 as primary signal was 
capable of inducing cell clustering and up-regulation of the 
expression of both ICAM-1 and L16, as well as of CD2 and 
VLA-5 antigen, on peripheral lymphocytes [38]. Simulta­
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neous presence of IL-4 reduced both the IL-2-induced cell 
clustering and the surface expression of these adhesion 
molecules [38]. The well-known inhibitory effect of IL-4 on 
IL-2-induced cell proliferation [38, 44, 45], prompted us to 
investigate more directly the role of adhesion structures in 
the lymphocyte proliferation response to IL-2.
2 Materials and methods
2.1 mAb
T he following mAb were used: NKI-L15 (anti-LFA-la, 
C D lla ,  IgG2a), NKI-L7 (anti-LFA-la, C D lla , IgG l; 
[46]), NKI-L16 (anti-LFA-la^ C D lla activation epitope, 
IgG2a; [43]), NKI-P1 (anti-CD44, IgGl; [47]), SAM-1 
(anti-VLA-5, CD49e, IgG2b, [48]), CLB-CD19 (anti- 
CD19, IgG2a; [49]), 1H4 (anti-CD20, IgGl), SPV-T3b 
(anti-CD3, IgG2a, [50]), CLB-T3/3 (anti-CD3, IgG2a; 
[30]), from R. van Lier, Amsterdam, CLB-LFA-1/1 (anti- 
LFA-lfl, CD18, IgGl; [51]), from F. Miedema, Amster­
dam , CLB-FcR-granl (anti-FcyRIII, CD 16, IgG2a; [52]), 
from  P. Tetteroo, Amsterdam, GoH3 (anti-VLA-6, CD49f, 
rat IgG2a; [53]), from A. Sonnenberg, Amsterdam, 60,3 
(anti-CD18, IgG2a; [25]), from M. Harlan, Seattle, Ts2/9 
(anti-LFA-3, CD58, IgGl, [54]), fromT. Springer, Boston, 
M A , HP1/3 (anti-VLA-4cx, CD49d, IgGl; [55]), from 
E  Sanchez-Madrid, Madrid, 4F2 (anti-4F2 activation anti­
gen, IgG2a; [56]), F10.2 (anti-ICAM-1, CD54, IgG l; [57]), 
F 103  (anti-ICAM-l, CD54, IgGl; [57]), both from 
A . Bloem, Utrecht, B-B10 (anti-p55 IL-2R, CD25, IgGl; 
[58]), from J. Wijdenes, Besancon, France,TU27 (anti-p75 
IL-2R, IgGl; [59]), from K. Sugamura, Sendai, Japan, leu 
19 (anti-CD56, IgGl, Becton Dickinson, San Jose, CA), 
ïeu M3 (anti-CD 14, IgG2b, Becton Dickinson), DAKO- 
CD25-FITC (anti-CD25, Dakopatts, Glostrup, Denmark), 
anti-p75 IL-2R-FITC (Endogen, Boston, MA), anti-HLA- 
DR-FITC (Becton Dickinson), phycoerythrine (PE) -  
labeled leu 54 (anti-CD54, Becton Dickinson).
2.2 Cells and medium
PBL from normal donors were isolated by Ficoll Hypaque 
density centrifugation and washed in Iscove’s medium 
(Flow Laboratories, Irvine, Scotland) supplemented with 
5% pooled, inactivated human serum (Central Laboratory 
of the Netherlands Red Cross Blood Transfusion Service, 
Amsterdam, The Netherlands), penicillin '100 IE/ml and 
kanamycin 100 [xg/ml (designated from here on as 
medium). As preactivated lymphocytes, PBL were used 
that were cultured for 4 days in the presence of rIL-2 500 
(Cetus) U/ml (kindly provided by EuroCetus, Amsterdam, 
The Netherlands). Small lymphocytes, containing over 
90% T cells, and large lymphocytes (LL), containing 
20-30% NK cells and 70-80% T cells, were isolated from 
the peripheral blood of nonnal donors by centrifugal 
élutriation as described previously [60]. Cell viability of all 
populations was greater than 95% as detected by trypan 
blue dye exclusion.
2*3 Enrichment for NK cells
Resting NK cells were enriched from peripheral blood 
buff}' coat by 1-h adherence to plastic at 37°C and depletion
Eur. J. Immunol. 1993. 23: 3292-3299
of B cells, T cells and activated cells using mAb directed to 
CD 19, CD3 and CD25, respectively and magnetic beads 
(Dynabeads, Dynal, Oslo, Norway) followed by selecting 
the negative cells on a FACStar cell sorter (Becton- 
Dickinson, Mountain View, CA).The resulting population 
contained at least 90% NK cells as determined by reactivity 
with CD56 and CD16 mAb and less than 1% T cells as 
tested with CD3 mAb.
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2.4 Proliferation assay
»
To determine the proliferative capacity of the cells, 5 x 104 
cells were incubated in round-bottom microtiter plates in a 
final volume of 200 [xl/well, in the presence of rIL-2, in the 
doses indicated, either with or without mAb directed to 
adhesion receptors or IL-2R mAb were used as 1/103 
diluted ascites or, were indicated, as purified mAb. For 
mAb NKI-L16, NKI-L15, CLB-LFA-1/1 and Ts2/9, 1/103
diluted ascites corresponded with 1 jig/ml, 10 jig/ml, 
1 jxg/ml and 8 jig/ml IgG, respectively. The ascites dilution 
used for the mAb in functional assays was pre-titrated to be 
optimal in the binding assays. Unless indicated otherwise, 
mAb and rIL-2 were added at the start of the culture. In 
some experiments, wells of the microtiter plate were coated 
with CD3 mAb (CLB-T3/3,1/106 diluted ascites), followed 
by washing the wells five times with medium before the 
lymphocytes, either with or without rIL-2, were added. 
After culture for 4 days (or as stated otherwise in kinetic 
experiments), cells were pulsed with 14.8 kBq per well of 
[3H]dThd (6,7 Ci/mmol, New England Nuclear, Boston, 
MA) for 4 h before being harvested as described previously 
[61], Data are expressed as mean cpm ± SD from triplicate 
cultures. In general, cells cultured in medium only gener­
ated less than 200 cpm. Statistical significance was calcu­
lated by comparison of experimental (antibody) values with 
controls in the same experiment using the paired i-text after 
logarithmic transformation of the data.
2.5 Aggregation assay
The formation of cell aggregates was determined by 
microscopic examination as described previously [38]. 
Briefly, cell clusters observed at the time of harvest of the 
culture were scored as the percentage of cells within clusters 
per total number of cells, x 100%. Scores ranged from: 
-  = <  10%, + = 10-50% to -++ = > 50%.
2.6 Immunofluorescence assay
Surface marker analysis of cells stained with mAb and 
FITC-labeled goat anti-mouse Ig (GAM-FITC) was deter­
mined by FACScan analysis (Becton Dickinson), as de­
scribed previously [38].
2.7 Assay for soluble p55 IL-2R
Soluble p55 IL-2R released in day 6 supernatants was 
assayed in duplicate using the soluble IL-2R ELISA kit of 
Eurogenetics (Tessenderlo, Belgium) according to the 
manufacturer’s instructions.
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3 Results
3.1 Involvement of LFA-1 in the rIL-2 response of small 
and large lymphocytes
In a previous study on the effect of IL-4 on IL-2-induced 
lymphocyte activation, it was found that cell aggregation, 
cell proliferation as well as expression of a number of 
adhesion receptors were co-regulated by both cytokines 
[38]. This prompted us to investigate whether adhesion 
receptors were directly involved in IL-2-mediated cell 
proliferation. Therefore small lymphocytes, representing a 
population enriched for T lymphocytes and depleted for 
monocytes and the bulk of NK cells, were incubated in the 
presence of rIL-2 either with or without mAb directed to a 
number of adhesion molecules known to be expressed on 
these cells. As shown in Table 1, only antibodies directed 
against the a subunit (NKI-L16, NKI-L15) or the ¡3 subunit 
(CLB-LFA-1/1) of LFA-1 inhibited the rIL-2-induced re­
sponse. Surprisingly, also the LFA-l-activating mAb NKI- 
L16 inhibited the proliferation, comparably to the effect of 
the adhesion blocking mAb NKI-L15. Inhibitory effects did 
not correlate to effects of the mAb on cell aggregation 
measured in parallel by microscopic examination (Table 1). 
Differences in the effects of mAb were not due to 
differences in specific antibody concentrations, since ail 
mAb were used at doses that were optimal for binding, and 
as shown in Table 1, effects on cell aggregation were 
apparent with most mAb. Lymphocytes that were pre­
activated in vitro by culture for 4 days in the presence of 
500 U/ml rIL-2, could no longer be blocked by NKI-L15 or 
CLB-LFA-1/1, but remained susceptible to inhibition by 
NKI-L16; although the latter inhibion was relatively weak, 
it was significant (p <  0.01) (Table 1).Table 2 indicates that 
the response of in vivo activated blasts (the fraction of large 
lymphocytes) to low dose rIL-2 (1 U/ml) was comparable to 
that of small, resting lymphocytes, but that their response 
to high dose rIL-2 (100 U/ml) was comparable to that of 
in vitro activated cells. The response of the in vivo activated 
blasts to high dose rIL-2 could not be blocked significantly
by either NKI-L15, CLB-LFA-1/1 or NKI-L16 (in all cases 
p > 0 .1). This indicated that the susceptibility to the 
inhibitory effect of LFA-1 mAb on the rIL-2 response was 
related to both the activation state of the cells and the 
strength of the rIL-2 stimulus.
Additional experiments using LL were set up to analyze the 
specificity of the inhibition of the LFA-1 mAb. As shown in 
Table 3, the proliferative response was also inhibited, 
although weakly (20-46%), by the anti-ICAM-1 mAb 
F10.2, indicating that LFA-l/ICAM-1 interaction was 
important for optimal responsiveness to IL-2. Comparable 
results were obtained using the ICAM-1 mAb F10.3 (data 
not shown). As shown in Fig. 1, a dose-dependent decrease 
in responsiveness to rIL-2 was obtained with purified 
LFA-1 mAb, ruling out the possibility that nonspecific 
ascites components were responsible for the inhibitory 
effects. Furthermore, it was excluded that the inhibition
Table 2 . Effect of LFA-1 directed mAb on the rIL-2 response of 
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a) LLwere obtained by centrifugal elutriation and were incubated 
at 5 x  104 cells/well in the presence of 100 U/ml rIL-2 or 1 U/ml 
rIL-2} without (control) or with mAb. After 4 days [3H]dThd 
incorporation was measured and expressed as % of control 
response. (Mean responses to 100 U/ml rIL-2 from all experi­
ments: 9 .2 c p m x l0 ”'3 (range 3.6-16.8), to 1 U/ml rIL-2: 
4.3 cpm X lO' 3 (range 1.4-9.7)).
Table 1, Effect of adhesion-associated mAb on the rIL-2 response of resting and pre-activated lymphocytes
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a) Resting cells (small lymphocytes obtained by centrifugal elutriation) or pre-activated lymphocytes (PBL pre-cultured for 4 days in the 
presence of 500 U/ml rIL-2) were incubated at 5 x 104 cells/well in the presence of 100 U/ml rIL-2 , without (control) or with mAb. 
After 4 days [3H]dThd incorporation was measured and data are expressed as % of control response (mean response to rIL-2 from all 
experiments with resting lymphocytes was 4.7 cpm x  10-3 (range 1.6-9.4); mean response to rIL2 from all experiments with 
pre-activated lymphocytes was 11.4 cpm x  10“ 3 (range 2.2-24.6). Background responses (medium or mAb only) were less than 5% of 
the rIL-2 response).
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Figure 1 .  Dose-dependent inhibition of rIL-2 induced proliferation 
by LFA-1 directed mAb. LL were incubated at 5 x  104 cells/well in 
the presence of 1 U/ml rIL-2 and different doses of purified mAb 
NKI-L16, NKI-L15, CLB-LFA-1/1 and Ts2/9. [3H]dThd incorpo­
ration from triplicate cultures was measured at day 4. mAb in the 
absence of rIL-2 did not induce proliferation over background 
levels. One out of two experiments is shown.
was Fc receptor mediated or due to a shift in the kinetics of 
the  response (data not shown).
(1 U/ml) and subsequently LFA-1 mAb were added at 
various time points. The data presented in Fig. 2 indicated 
that under the conditions used, LFA-l/ICAM-1 interaction 
during the first 24 h of culture determined optimal respon­
siveness to rIL-2 and that addition of blocking mAb 
NKI-L15 or CLB-LFA-1/1 after this initial phase did not 
influence the reaction. This interval was found to be 
dependent on the dose of rIL-2 used, being shorter with 
higher doses of rIL-2 (data not shown). Fig. 2 furthermore 
shows, thatNKI-L16 inhibited the rIL-2-induced response, 
irrespective of the time of addition to the culture.
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3.2 LFA-l/ICAM-1 interaction during early phase of 
culture determines responsiveness to rIL-2
To assess in which phase of the culture cell-cell contact was 
important, the LL were incubated in the presence of rIL-2
mAb, LL were incubated at 5 X 104 cells/well in the presence of 
'1 U/ml rIL-2 and LFA-1 mAb were added at the time points 
indicated. [3H]dThd incorporation from triplicate cultures was 
measured at day 4. One experiment representative of three is 
shown.
Table 3.
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a) LL were incubated at 5 X 104 cel]s/well in 
the presence or absence of rIL-2 (1 U/ml) 
and mAb F10.2. Data are expressed as 
cpm x  10~3 ±  SD from triplicate cultures 
harvested at day 4.
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3.3 LFA-1 mAb selectively block p55 IL-2R-mediated 
responses to rIL-2
To analyze further whether a particular pathway of rIL-2 
activation was affected by blockade of LFA-l/ICAM-1 
interaction, LL were incubated in the presence of rIL-2
(100 U/ml) and CLB-LFA-1/1, either with the p55 IL-2R 
mAb B-B10, the p75 IL-2RTU27 or a combination of both 
mAb. As shown in Fig. 3, in the presence of B-B10, 
allowing interaction of rIL-2 with p75, CLB-LFA-1/1 
hardly affected the rIL-2 response. However, in the pres­
ence of TU27, allowing interaction of rIL-2 with p55, 
CLB-LFA-1/1 profoundly reduced rIL-2 reactivity. Similar 
results were obtained with NKI-L15 or NKI-L16 (data not 
shown). This strongly suggested that either blocking or 
strongly enhancing the LFA-l/ICAM-1 interaction resulted 
in selective impairment of p55-mediated, high-affinity 
responses to rIL-2.
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Figure 3. Inhibitory effect of CLB-LFA-1/1 on the p55 mediated 
rIL~2 response. LL were incubated in the presence of 100 U/ml 
rIL-2 either with or without mAb to CD 18 (CLB-LFA-1/1) or 
CD58 (Ts2/9), in the presence or absence of p55 IL-2R directed 
mAh B-B10 and/or p75 IL-2R directed mAb TU27. [3H]dThd 
incorporation from triplicate cultures was measured at day 4. One 
experiment representative of five is shown.
3.4 Differential effects of LFA-1 inAb on NK cell- and 
T cell-enriched populations
NK cells. However, NKI-L16 was capable of reducing NK 
ceil rIL-2 reactivity, but only of p55-mediated, and not of 
p75-mediated responses.
Alternatively,T cells were investigated for their susceptibil­
ity to be inhibited by LFA-1 mAb in their responsiveness to 
rIL-2. Small lymphocytes, composed of over 90% T cells 
and less than 5% NK cells, were stimulated with a 
suboptimal dose of CD3 mAb (1/106 diluted ascites, which 
gives approximately 1% of the proliferation of an optimal 
anti-CD3 response) and rIL-2, either with or without 
LFA-1 mAb NKI-L16, NKI-L15 or CLB-LFA-1/1, or as 
control, LFA-3 mAb Ts2/9. The data, shown in Table 4, 
indicate that NKI-L15, NKI-L16 and CLB-LFA-1/1 were 
inhibiting responsiveness to rIL-2 whereas Ts2/9 had 
almost no effect. Additional experiments, using Tceli 
clones generated to EBV-transformed allogeneic B cells, 
indicated that responses of activated T lymphocytes to 
rIL-2 could not be blocked by CLB-LFA-1/1 or Ts2/9 and 
only to some extent by NKI-L16 (mean response to 
rIL-2 ± SD in the presence of mAb, as percentage of the 
control without mAb, from 10 separate experiments was 
102 ± 12, 99 ± 13, 72 ± 12, respectively).
These data indicate that resting NK cells were inhibited in 
their responsiveness to rIL-2 only by LFA-1 mAb NKI-L16, 
but that resting T lymphocytes could be inhibited by both 
NKI-L16 and CLB-LFA-1/1.
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To determine whether NK cells and T cells would be 
equally susceptible to the inhibitory effect of LFA-1 mAb, 
cell depletion experiments were performed as described in 
Sect. 2.3. NK cell-enriched populations (containing less 
than 1% T cells) were incubated in the presence of rIL-2 
100 U/ml either with or without IL-2R-directed mAb, in 
the presence or absence of LFA-1 mAb NKI-L16 or 
CLB-LFA-1/1, or as control, LFA-3 mAbTs2/9. As shown 
in Fig. 4, CLB-LFA-1/1 did not inhibit the rIL-2 response of
Figure 4.  Differential effects of LFA-1 directed mAb on the 
response to rIL-2 of NK cell-enriched populations. NK cell- 
enriched cell populations were incubated at 5 X 104 cells/well in 
triplicate cultures in the presence or absence of rIL-2 (100 U/ml) 
and mAb and harvested for [3H]dThd incorporation at day 4. Data 
are presented as the mean % of control responses (to rIL-2 
only) ±  SD from three separate experiments (responses to rIL-2: 
10.8,15.1, and 19.0 cpm x 103, respectively; absolute cpm x  10“ 3 
to rIL-2 in the presence of TU27 and B-B10: 3.4, 18.5, 16.6, and 
5.0, 12.0, 22.7, respectively).
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NK.I-L15
NKI-L16
CLB-LFA-1/1
TS2/9
B-B10
presence ofa) present
cpm x  10~3 
±  SD
Mean fluorescence intensity 
(% positive ceils)
CD25 p75 HLA-DR CD54
Table 4. Inhibitory effect of LFA-1 mAb on T cell proliferation and surface antigen expression upon stimulation with suboptimal 
anti-CD3 plus rIL-2
a) T cells (small lymphocyte fraction) were incu­
bated at 5 x  104 cells/well in suboptimal anti- 
CD3 (1:106 diluted), either with or without rIL-2 
(10 U/ml) and/or mAb for 6 days. Data are ex­
pressed as [3H]dThd incorporation from tripli­
cate cultures, and as mean fluorescence intensity 
(% positive cells). Cells cultured in the presence 
of mAb, but without rIL-2, did not proliferate 
above background level (in the presence of 
suboptimal anti-CD 3 only). Neither did mAh 
alone change the background surface antigen 
expression. One experiment representative of 
four to six is shown.
b) N .D,, not determined.
0 .2  ± 0 / 1  
41.7 + 1.6
22.6 ±  2.5
11.6 ± 1.1 
8 .0  ±  0.1
33.9 ±  4.0 
1.9 ± 0 .1
8(11)
165(63)
100(52)
45(34)
30(24)
22(19)
20(20)
192(17)
594(63)
707(58)
518(47)
29(64)
81(28) 23(20) 247(32)
537(65) 
151(18)
160(62)
N .D .15) 22(20)
66(80)
65(76)
67(77)
32(70)
Table 5. Effect of LFA-1 mAb on the level of soluble p55IL-2R in 
cultures stimulated with suboptimal anti-CD3 and rIL-2a)
mAb rIL-2 present Soluble p 5 5IL-2R (U/ml)
NKI-L15 
NKI-L16 
CLB-
+
119+  9 
117 ±  0.7 
186 ±  10
179 ±  8
139 ±  9
180 ±  0,7
T cells (small lymphocyte fraction) were incubated at 5 x 104 
cells/well in suboptimal anti-CD3 (1 :106 diluted), either with or 
without rIL-2 (10 U/ml) and/or mAb. Supernatants from 
triplicate cultures were pooled at day 6 and assayed in duplicate 
for soluble p55IL-2R. Data are expressed as the mean ± SD 
from two separate experiments.
3*5 Effect of LFA-1 mAb on the activation state of T 
lymphocytes
To establish effects of LFA-1 mAb on the activation state of 
iTL-2-stimulated cells,T lymphocytes were stimulated with 
a  suboptimal concentration of CD3 mAb and rIL-2, in the 
presence of either LFA-1 mAb NKI-L15, NKI-L16, CLB- 
LFA-1/1 or the control Ts2/9. After 4 days of culture, the 
cells were stained with FITC-conjugated mAb directed to 
p55 IL-2R, p75 IL-2R, HLA-DR and ICAM-1. The data 
show that CLB-LFA-1/1 and NKI-L16, and to a lesser 
extent NKI-L15, prevented activation of the lymphocytes 
as shown by decreased percentages of cells expressing p55 
and HLA-DR. Inhibition of surface antigen expression was 
observed concomitantly with inhibition of cell proliferation 
(Table 4). Expression of p75 or ICAM-1 was not decreased 
by LFA-1 or LFA-3 mAb (Table 4), whereas the antigen 
density of the latter was reduced by anti-p55 1L-2R mAb 
B-B10 (data not shown). In addition, CLB-LFA-1/1 
reduced the release of soluble p55 IL-2R, whereas NKI- 
L15, NKI-L16 and Ts2/9 showed no effect or slightly 
increased the level of this receptor in the supernatant 
(Table 5).
4 Discussion
The data obtained in the present study indicate that resting 
peripheral T lymphocytes require LFA-l/ICAM-1 interac­
tions for optimal responsiveness to IL-2. Previous studies 
have shown the involvement of these adhesion molecules in 
cell proliferation induced by TCR triggering by antigen, 
allo-antigen or mitogen [23-34]. Our findings extend these 
observations in several aspects: (1) the inhibitory affects of 
LFA-1 mAb are observed with cells stimulated with IL-2 as 
the primary signal; (2) the extent of inhibition of respon­
siveness to rIL-2 depends on the state of activation of the 
lymphocytes and on the levels of rIL-2 used; (3) prevention 
of LFA-l/ICAM-1 interactions selectively impairs p55 
rIL-2R~ mediated responses, but does not affect interaction 
of IL-2 with the intermediate p75 IL-2R; (4) the require­
ment for the LFA-l/ICAM-1 pathway in IL-2 reactivity is 
restricted to T lymphocytes, and is not observed for NK 
cells; (5) strengthening of LFA-l/ICAM-1 interactions can 
also lead to reduced responsiveness to rIL-2.
First, it was of interest to investigate whether blocking of 
the LFA-l/ICAM-1 and CD2/LFA-3 pathways of cell 
interaction would directly interfere with the proliferative 
response of the cells in response to IL-2. Despite the fact 
that both LFA-1 and LFA-3 mAb are known to profoundly 
inhibit cell conjugate formation [22,36, 62], only the 
former inhibited the rIL-2 proliferation response, irrespec­
tive of their effect on cell aggregation (Table 1).
To discriminate which IL-2 activation route was blocked by 
LFA-1 mAb, either that initiated through interaction of 
IL-2 with p75 or through interaction of IL-2 with the 
high-affinity receptor, or both, experiments were per­
formed with blocking mAb specifically directed to the 
IL-2R subunits p55 and p75. The results show that rIL-2 
responses mediated through the p55 a chain are inhibited 
by LFA-1 mAb, whereas rIL-2 responses mediated through 
p75 only, are unaffected. This finding strongly argues in 
favor of a functional relationship between p55 and com­
ponents of the LFA-l/ICAM-1 adhesion route, as proposed 
by the group of Waldmann [63, 64], These investigators 
showed a partial association of p55 and ICAM-1 on cells of 
the HTLV-l-positive Tcell line HUT-102 [63, 64]. Our 
attempts to reveal any association of p55 and ICAM-1 
molecules on the surface of PBL, LL, rIL-2-activated PBL 
or T cell clones, either by co-modulation studies using the 
FACS or by microscopic examination of fluorochrome- 
labeled cells, were negative (data not shown). Therefore, 
although it remains to be established whether these 
molecules are associated on peripheral lymphocytes, such 
association might explain our present findings; inhibition of 
cell-cell contact would prevent a locally, high level of IL-2 to
bind to the low-affinity IL-2R p55 supposedly present at the 
site of cell-cell contact. Thus, subsequent rapid up-regula- 
tion of p55 would be prevented, resulting in reduced 
activation. Since T cells [5] in contrast to NK cells [65] are 
capable of producing IL-2 in response to the exogenous 
IL-2 signal, such a hypothesis may explain our finding that 
T lymphocytes, but not NK cells, are inhibited in their 
responsiveness to rIL-2 by the blocking LFA-1 mAb 
CLB-LFA-1/1.
Literature data show that LFA-1 may serve both as an 
adhesion receptor as well as a signaling molecule [30-34].
In our study, upon stimulation with CD3 mAb in the 
presence of suboptimal rIL-2 levels, NKI-L15 and NKI-L16 
were found to potentiate responses (data not shown). 
Under optimal IL-2 stimulation of T cells, the main func­
tion of LFA-l/ICAM-1 interaction is to provide cell-cell 
contact, as shown by the finding that both LFA-1 a and 
LFA-1/3 mAb block the response (Table 4).
m
T lymphocytes from patients, suffering from the leukocyte 
adhesion deficiency (LAD) syndrome, which fail to express 
LFA-1 on their cell surface, show impaired proliferative 
responsiveness to mitogenic and antigenic triggering [66]. 
However, repetitive stimulation ultimately results in a level 
of proliferation, comparable to that of normal lympho­
cytes, despite lack of LFA-1 expression of the expanded cell 
population [66]. This may be explained by assuming that 
LAD T lymphocytes can be induced by antigenic triggering 
to express minimal levels of IL-2R, but fail to up-regulate 
these receptors in the presence of exogenous IL-2. Only 
after repetitive TCR stimulation, p55 IL-2R may be 
expected to be up-regulated, via endogenous routes, to a 
level sufficient to bind exogenous IL-2.
In addition, our data indicate that not only blocking LFA-1 
mAb, but also the adhesion-inducing mAb NKI-L16 inhib­
ited proliferation in response to rIL-2. In comparison with 
the LFA-1 (3 mAb CLB-LFA-1/1 or the LFA-1 a mAb 
NKI-L15, inhibition by NKI-L16 was found to be less 
dependent on the state of activation of the cells, on the 
strength of the rIL-2 stimulus or on the kinetics of addition 
to the culture, suggesting that its action was not restricted 
to an early phase of the IL-2 activation process. Moreover, 
NKI-L16 reduced the activation of the T lymphocytes to a 
lesser extent than CLB-LFA-1/1 as determined by pheno­
type analysis and the release of soluble p55 IL-2R, NKI-L16 
was shown to profoundly inhibit the p55-, but not the 
p75-mediated response of NK cells to IL-2, suggesting that 
its target too was the high-affinity IL-2R. In addition, this 
indicated that strong cluster formation itself was not 
responsible for the observed inhibition of proliferation. 
Presumably, the strong activation of the LFA-1 molecule 
induced by NKI-L16, which leads to prolonged increased 
interaction with ICAM-1 [38, 39,41, 42], results in reduced 
mobility of the putatively associated p55, which may 
explain the inhibitory effect of NKI-L16. Further experi­
ments should prove whether this hypothesis is correct. 
Although tested with different cells (HUT-102), lateral 
diffusion measurements by Eclidin and coworkers [67] have 
indicated that immobilization of ICAM-1 can lead to 
reduced mobility of p55.The effect of the anti-LFA-1 mAb 
24 that locks the high-affinity state of LFA-1 in antigen- 
stimulated cultures and concomitantly inhibits cell prolifer­
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ation [68], bears resemblance to the effect of NKI-L16 and 
may be explained similarly.
In conclusion, our data indicate that cell-cell contact 
through LFA-l/ICAM-1 interactions provides the T lym­
phocyte with an important tool for rapidly up-regulating its 
high affinity IL-2R to effectively respond to IL-2.
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